Co-inhibition of PD-1 and CTLA-4 has an antitumor effect in patients with OCCC, but with severe adverse events [1, 2]; however, a randomized phase III study on melanoma revealed that co-inhibition of PD-1 and LAG-3 leads to favorable outcomes [8]. Here, LAG3 is linked to melanoma.